Neil Torbett

Neil is an experienced biotechnology professional with over 15 years of research and management experience. He joined PhoreMost in January 2017, serving as Chief Business Officer before being appointed as Chief Operating Officer in July 2020 and CEO as of March 2022.

Prior to PhoreMost, Neil co-founded Activiomics Ltd, where he served as Chief Operating Officer of Activiomics until its acquisition by hVIVO in 2014, after which he was engaged in the establishment of R&D activities as Director of Discovery Research. Previously, Neil worked at Piramed Pharma, where he was involved in the management of a successful research collaboration with Genentech focused on the discovery and development of PI3-kinase inhibitors for cancer. Piramed was sold to Roche in 2008.

Neil holds a BSc in Biology from the University of York and a Ph.D. from the Protein Phosphorylation laboratory at the Cancer Research UK London Research Institute after which he completed postdoctoral training at the University of California San Francisco Cancer Center. In 2019 Neil was awarded an MBA from The Open University.